A recent safety trial has found a promising new therapy for type 1 diabetes that uses patients’ own regulatory T-cells instead of the usual immunosuppressive drugs to protect beta cells.
Many current treatments for type 1 diabetes (T1D) have been designed with the aim of suppressing immune response to prevent a person’s immune system from attacking his or her own insulin-secreting beta cells in the pancreas. However, at the same time, these treatments can leave the body vulnerable to infection or cancer.
A recent safety trial led by UC San Francisco (UCSF) researchers has found a promising new therapy that uses patients’ own regulatory T-cells (Tregs) instead of the usual immunosuppressive drugs to protect beta cells. In the body, Tregs naturally suppress immune responses of other cells while holding potential autoimmune over-responses in check. In other words, the use of Tregs in the UCSF trial was justified based on the concept of “immune tolerance”—as reported in Science Translational Medicine—“these cells may have the capability to dampen the immune system’s assault on beta cells while leaving its infection-fighting capabilities intact.”
The UCSF trial included 14 patients between 18 and 43 years of age with recent-onset T1D. They were organized into 4 groups, which received different volumes of Treg infusions—the lowest being 5 million cells and the greatest being 2.6 billion. To collect the Tregs, doctors removed around 2 cups of blood from each patient and isolated the Tregs from the rest of the blood components before placing them in a growth medium. The Tregs were augmented in number by almost 1500 times and then infused back into their trial participant.
A subset of the transferred Tregs was long-lived, with up to 25% of the peak level still remaining in the patient’s blood 1 year after transfer. Immune studies also showed increases in Treg level and broad retention of Treg types in recipients. No patient from any of the groups experienced any serious side effects.
Even though the trial tested safety results instead of efficacy, these results are still a promising first step towards a complete therapy and, as the trial’s research team wrote, support the development of a Phase 2 trial to test efficacy.
“Using a patient’s own cells—identifying them, isolating them, expanding them, and infusing them back into the patient—is an exciting new pillar for drug development,” primary report author Jeffrey Bluestone, PhD, said. “This could be a game-changer. For type 1 diabetes, we’ve traditionally given immunosuppressive drugs, but this trial gives us a new way forward. By using Tregs to ‘re-educate’ the immune system, we may be able to really change the course of this disease.”
Bluestone also discussed the potential value of Treg therapy to be expanded into use as treatment for other immune diseases such as rheumatoid arthritis and lupus, and even cardiovascular and neurological diseases in the future.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Technology Takes Center Stage at the 2025 AAD Annual Meeting
March 14th 2025The role of artificial intelligence, DataDerm, and telehealth in advancing dermatology care was discussed throughout the meeting, with experts highlighting their potential regarding patient access and health equity.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More